As the 13th International AIDS Society (IAS) Conference on HIV Science continues in Kigali, Rwanda, it comes at a critical juncture for global HIV response efforts.
Amid growing scientific innovation and tightening global health budgets, Kenya is emerging as a key player in piloting next-generation prevention tools-chief among them, lenacapavir.
On July 14, the World Health Organisation (WHO) approved a new HIV prevention drug called lenacapavir. It's an injection given just twice a year and helps protect people from getting HIV.
The drug works by stopping the virus from multiplying in the body.
